Loading patent…
AssigneesThe Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
InventorsGerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
Estimating the term…
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
A composition, comprising an isolated peptide that selectively binds to Staphylococcal poly-N-acetyl glucosamine (PNAG) and comprises the amino acid sequences of SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:21.
An isolated anti-Staphylococcal PNAG monoclonal antibody produced by an isolated cell producing an anti-Staphylococcal PNAG monoclonal antibody and having ATCC Accession No. PTA-5933, or a fragment thereof, wherein the fragment is selected from the group consisting of an F(ab')2 fragment, an Fd fragment, and an Fab fragment.
Dependencies are inferred from the claim text.